Literature DB >> 17143907

Patent foramen ovale and migraine.

M C Post1, J G L M Luermans, H W M Plokker, W Budts.   

Abstract

Migraine is a common neurological disorder with a great impact on the quality of life and social activities. The patent foramen ovale (PFO) is an intra-atrial right-to-left shunt with a prevalence of 25% in the general population. An increased prevalence is found in patients with migraine, especially in migraine with aura. Percutaneous PFO closure might decrease the prevalence of migraine. However, most of these observational studies were retrospective without a randomized design and the results need to be interpreted with caution. In this review we describe the association between PFO and migraine and the different pathophysiological hypotheses, which have been proposed to explain this relationship. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17143907     DOI: 10.1002/ccd.20931

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  3 in total

1.  Patent foramen ovale closure.

Authors:  Zahid Amin
Journal:  Ann Pediatr Cardiol       Date:  2010-01

2.  Patent Foramen Ovale With Atrial Septal Aneurysm Is Strongly Associated With Migraine With Aura: A Large Observational Study.

Authors:  Roel J R Snijder; Justin G L M Luermans; Albert H de Heij; Vincent Thijs; Wouter J Schonewille; Alexander Van De Bruaene; Martin J Swaans; Werner I H L Budts; Martijn C Post
Journal:  J Am Heart Assoc       Date:  2016-12-01       Impact factor: 5.501

3.  Clopidogrel can be an effective complementary prophylactic for drug-refractory migraine with patent foramen ovale.

Authors:  Yichen Guo; Yujie Shi; Dan Zhu; Rui Liu; Yi Qi; Guogang Luo
Journal:  J Investig Med       Date:  2020-08-26       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.